ES2436344B1 - Pharmaceutical composition of diacetylmorphine and naloxone for oral administration - Google Patents

Pharmaceutical composition of diacetylmorphine and naloxone for oral administration Download PDF

Info

Publication number
ES2436344B1
ES2436344B1 ES201230814A ES201230814A ES2436344B1 ES 2436344 B1 ES2436344 B1 ES 2436344B1 ES 201230814 A ES201230814 A ES 201230814A ES 201230814 A ES201230814 A ES 201230814A ES 2436344 B1 ES2436344 B1 ES 2436344B1
Authority
ES
Spain
Prior art keywords
diacetylmorphine
naloxone
oral administration
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201230814A
Other languages
Spanish (es)
Other versions
ES2436344A1 (en
Inventor
Rosa Pardina Clar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OneDose Pharma SL
Original Assignee
OneDose Pharma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OneDose Pharma SL filed Critical OneDose Pharma SL
Priority to ES201230814A priority Critical patent/ES2436344B1/en
Priority to PCT/ES2013/070272 priority patent/WO2013178846A1/en
Publication of ES2436344A1 publication Critical patent/ES2436344A1/en
Application granted granted Critical
Publication of ES2436344B1 publication Critical patent/ES2436344B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica de diacetilmorfina y naloxona para administración oral; que comprende diacetilmorfina o una de sus sales farmacéuticamente aceptables, naloxona o una de sus sales farmacéuticamente aceptables y al menos un excipiente farmacéuticamente aceptable, con una relación ponderal entre diacetilmorfina:naloxona está comprendida entre 24:1 y 26:1. La invención también comprende un comprimido con esta composición y el uso de dicha composición o comprimido para la preparación de un medicamento para el tratamiento de la adicción a sustancias opioides.Pharmaceutical composition of diacetylmorphine and naloxone for oral administration; comprising diacetylmorphine or one of its pharmaceutically acceptable salts, naloxone or one of its pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient, with a weight ratio between diacetylmorphine: naloxone is between 24: 1 and 26: 1. The invention also comprises a tablet with this composition and the use of said composition or tablet for the preparation of a medicament for the treatment of addiction to opioid substances.

Description



imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

Claims (1)



 imagen1image 1
ES201230814A 2012-05-29 2012-05-29 Pharmaceutical composition of diacetylmorphine and naloxone for oral administration Expired - Fee Related ES2436344B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201230814A ES2436344B1 (en) 2012-05-29 2012-05-29 Pharmaceutical composition of diacetylmorphine and naloxone for oral administration
PCT/ES2013/070272 WO2013178846A1 (en) 2012-05-29 2013-04-30 Pharmaceutical composition comprising diacetylmorphine and naloxone for oral administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230814A ES2436344B1 (en) 2012-05-29 2012-05-29 Pharmaceutical composition of diacetylmorphine and naloxone for oral administration

Publications (2)

Publication Number Publication Date
ES2436344A1 ES2436344A1 (en) 2013-12-30
ES2436344B1 true ES2436344B1 (en) 2014-08-07

Family

ID=49672511

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201230814A Expired - Fee Related ES2436344B1 (en) 2012-05-29 2012-05-29 Pharmaceutical composition of diacetylmorphine and naloxone for oral administration

Country Status (2)

Country Link
ES (1) ES2436344B1 (en)
WO (1) WO2013178846A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002319774B2 (en) * 2001-08-06 2005-04-21 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
EP1551372B8 (en) * 2002-09-20 2018-08-01 Alpharma Pharmaceuticals LLC Sequestering subunit and related compositions and methods
EP1810714A1 (en) * 2006-01-19 2007-07-25 Holger Lars Hermann Use of a combination of heroin and naloxon for drug substitution
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
EP1897544A1 (en) * 2006-09-05 2008-03-12 Holger Lars Hermann Opioid agonist and antagonist combinations

Also Published As

Publication number Publication date
ES2436344A1 (en) 2013-12-30
WO2013178846A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
ES2409069B2 (en) Use of binders to manufacture stable storage formulations
ES2551307T3 (en) Inhalation composition containing aclidinium for the treatment of chronic obstructive pulmonary disease
CL2013001885A1 (en) Compounds derived from morphine, peripheral ipiode receptor antagonists; pharmaceutical composition; oral formulation; and use to reduce the side effects of opioid therapy (div. sol. 905-08).
BR112012024019A2 (en) controlled release dosage form and method for releasing a drug
CL2014001450A1 (en) Solid controlled release dose form comprising an opioid analgesic dispersed in a matrix material; Preparation method; use in the treatment of pain.
AR065809A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR
CL2007001870A1 (en) PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE INCLUDING VALSARTAN, AMLODIPINA, HYDROCHLOROTIAZIDA AND PHARMACEUTICALLY ACCEPTABLE ADDITIVES; PREPARATION PROCEDURE; AND USE FOR THE TREATMENT OF HYPERTENSION, CARDIAC INSUFFICIENCY, INFARTO D
CL2015002733A1 (en) Pharmaceutical composition of s-ketamine hydrochloride.
GT200600445A (en) SOLID PHARMACEUTICAL PRESENTATION FORMS OF ORAL ADMINISTRATION WITH QUICK RELEASE OF THE ACTIVE PRINCIPLE.
AR055099A1 (en) LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES
DOP2010000299A (en) USE OF DRONEDARONA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR MORTALITY
JP2016501828A5 (en)
AR084620A1 (en) A COMBINATION OF AN OPIACE AGONIST AND AN OPIACE ANTAGONIST IN THE TREATMENT OF PARKINSON'S DISEASE
BRPI0814666A2 (en) pharmaceutical composition for oral administration, use of a formulation. process for preparing a solid dosage form, and, solid dosage form
AR088232A1 (en) PHARMACEUTICAL COMPOSITIONS
CL2014001828A1 (en) Dual-release oral dosage system comprising doxylamine and pyridoxine and / or its analogs, metabolites and salts thereof; oral dosage form dual release; pharmaceutical kit; use to relieve symptoms of nausea and vomiting, including those of pregnancy.
CL2015001615A1 (en) A pharmaceutical composition comprising vortioxetine and donepezil together with a pharmaceutically acceptable excipient; and its use for the treatment of cognitive dysfunction, dementia in Alzheimer's disease, cognitive dysfunction associated with depression and schizophrenia, among other diseases.
BR112014014795A2 (en) immediate release multi-unit pellet system
CR20140540A (en) NEW DOSAGE FORM AND FORMULATION OF ABEDITEROL
AR092356A1 (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN AND METHOD OF PREPARATION OF THE FORMULATION
PE20120956A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BUPRENORPHINE AND NALMEFENE
IT1401284B1 (en) NEW PHARMACEUTICAL FORMULATIONS SUITABLE FOR ORAL ADMINISTRATION OF DIHYDRATE ESOMEPRAZOLE MAGNESIUM, IN THE FORM OF MUPS TABLETS (MULTI UNIT PELLETS SYSTEM).
UY31887A (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR USE IN THE PREVENTION OF CARDIOVERSION
CL2013003176A1 (en) Sustained-release oral pharmaceutical formulation comprising two tablets containing 1000 mg of paracetamol, which is present in a sustained-release layer and another of immediate release, in a proportion of paracetamol per layer of 80-90%: 10-20% , where the unit dose comprises 2000 mg paracetamol.
BRPI0817863A2 (en) Mechanical protection layer for a dosage form, pharmaceutically acceptable solid dosage form, tablet, use of a mechanical protection layer and methods for preparing a mechanical protection layer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2436344

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140807

FD2A Announcement of lapse in spain

Effective date: 20230926